Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
53,369,776
-
Share change
-
-2,184,238
-
Total reported value
-
$958,514,173
-
Put/Call ratio
-
45%
-
Price per share
-
$17.96
-
Number of holders
-
157
-
Value change
-
-$149,964,792
-
Number of buys
-
82
-
Number of sells
-
99
Institutional Holders of CLOVIS ONCOLOGY INC - COM (CLVSQ) as of Q4 2018
As of 31 Dec 2018,
CLOVIS ONCOLOGY INC - COM (CLVSQ) was held by
157 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
53,369,776 shares.
The largest 10 holders included
Palo Alto Investors LP, ARMISTICE CAPITAL, LLC, Vanguard Group Inc, BlackRock Inc., Redmile Group, LLC, STATE STREET CORP, Camber Capital Management LP, ORBIMED ADVISORS LLC, FMR LLC, and SAMLYN CAPITAL, LLC.
This page lists
157
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.